A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Woohyeun | - |
dc.contributor.author | Chang, Kiyuk | - |
dc.contributor.author | Cho, Eun Joo | - |
dc.contributor.author | Ahn, Jeong-Cheon | - |
dc.contributor.author | Yu, Cheol Woong | - |
dc.contributor.author | Cho, Kyoung-Im | - |
dc.contributor.author | Kim, Yong-Jin | - |
dc.contributor.author | Kang, Duk-Hyun | - |
dc.contributor.author | Kim, Seok-Yeon | - |
dc.contributor.author | Lee, Sang-Hak | - |
dc.contributor.author | Kim, Ung | - |
dc.contributor.author | Kim, Shin-Jae | - |
dc.contributor.author | Ahn, Young Keun | - |
dc.contributor.author | Lee, Chang Hoon | - |
dc.contributor.author | Shin, Jin Ho | - |
dc.contributor.author | Kim, Mikyung | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.date.accessioned | 2021-08-31T11:22:37Z | - |
dc.date.available | 2021-08-31T11:22:37Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57787 | - |
dc.description.abstract | This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia. A total of 106 patients of 15 institutions in Korea were randomly assigned to 1 of 3 treatment groups: rosuvastatin 20 mg + amlodipine 10 mg, amlodipine 10 mg, or rosuvastatin 20 mg. After 8 weeks of treatment, the mean +/- SD of change in mean sitting systolic blood pressure (msSBP) was -22.82 +/- 12.99 mm Hg in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. The percentage of patients whose msSBP decreased >= 20 mm Hg or msDBP decreased >= 10 mm Hg was also highest in this group (74.29%). The mean +/- SD percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline after 8 weeks was -52.53% +/- 11.21% in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. More patients in the rosuvastatin + amlodipine group achieved their target LDL-C goal at 8 weeks, compared with the other treatment groups (97.14%). No serious adverse events or adverse drug reactions were observed in all groups. In hypertensive patients with dyslipidemia, combination treatment with rosuvastatin 20 mg + amlodipine 10 mg effectively reduced blood pressure and LDL-C levels while maintaining safety. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | SYSTEMATIC ANALYSIS | - |
dc.subject | GLOBAL BURDEN | - |
dc.subject | METAANALYSIS | - |
dc.subject | PREVALENCE | - |
dc.subject | STATINS | - |
dc.subject | AMLODIPINE/ATORVASTATIN | - |
dc.subject | ADHERENCE | - |
dc.subject | THERAPY | - |
dc.subject | HYPERCHOLESTEROLEMIA | - |
dc.title | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ahn, Jeong-Cheon | - |
dc.contributor.affiliatedAuthor | Yu, Cheol Woong | - |
dc.contributor.affiliatedAuthor | Park, Chang Gyu | - |
dc.identifier.doi | 10.1111/jch.13774 | - |
dc.identifier.scopusid | 2-s2.0-85078832449 | - |
dc.identifier.wosid | 000510309300001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.22, no.2, pp.261 - 269 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 22 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 261 | - |
dc.citation.endPage | 269 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | SYSTEMATIC ANALYSIS | - |
dc.subject.keywordPlus | GLOBAL BURDEN | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | STATINS | - |
dc.subject.keywordPlus | AMLODIPINE/ATORVASTATIN | - |
dc.subject.keywordPlus | ADHERENCE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | HYPERCHOLESTEROLEMIA | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | dyslipidemia | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | rosuvastatin | - |
dc.subject.keywordAuthor | single-pill combination | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.